^
    Back
    Association details:
    Biomarker:HSPA1A elevation
    Cancer:Melanoma
    Drug Class:PD1 inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Sci Transl Med
    Title:

    Tumor-intrinsic NLRP3-HSP70-TLR4 axis drives premetastatic niche development and hyperprogression during anti–PD-1 immunotherapy

    Published date:
    11/06/2022
    Excerpt:
    Elevated baseline concentrations of plasma HSP70 and evidence of NLRP3 signaling activity in tumor tissue specimens correlated with the development of disease hyperprogression and inferior survival in patients with stage IV melanoma undergoing anti–PD-1 immunotherapy.
    DOI:
    10.1126/scitranslmed.abq7019